Skip to content

Clinical trials

Phase 2 Breast Neoplasms trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Breast Neoplasms Phase: Phase 2 Clear all

2,817 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
200045
200143
200270
200375
200499
2005100
2006111
2007131
2008128
2009117
2010109
2011108
201298
2013105
201496
2015116
2016101
2017102
201869
2019108
2020112
2021103
202299
2023114
2024109
2025119
2026121

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed1,297
Terminated419
Unknown status362
Recruiting319
Active, not recruiting189
Withdrawn112
Not yet recruiting111
Enrolling by invitation5
Suspended3

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Cancer Institute (NCI)94
Fudan University80
Dana-Farber Cancer Institute53
Hoffmann-La Roche49
M.D. Anderson Cancer Center49
Memorial Sloan Kettering Cancer Center48
Eli Lilly and Company39
Pfizer36
Novartis Pharmaceuticals32
Alliance for Clinical Trials in Oncology31

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Breast Neoplasms2,817
Triple Negative Breast Neoplasms181
Neoplasm Metastasis150
Breast Neoplasms, Male99
Neoplasms99
Lung Neoplasms70
Ovarian Neoplasms63
Carcinoma, Non-Small-Cell Lung60
Brain Neoplasms56
Carcinoma, Intraductal, Noninfiltrating48

Trials

Showing 1 to 25 of 2,817. Each trial links to its page on Pharma Observatory.

2,717 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.